{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:10:36Z","timestamp":1757542236316,"version":"3.37.3"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013276","name":"Interreg","doi-asserted-by":"publisher","award":["MAC2\/1.1a\/219"],"award-info":[{"award-number":["MAC2\/1.1a\/219"]}],"id":[{"id":"10.13039\/100013276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Malaria and Human Immunodeficiency Virus infections are among the top 10 causes of death in low income countries. Furthermore, many medicines used in these treatment areas are substandard, which contributes to the high death rate. Using a monitoring system to identify substandard and falsified medicines, the study aims to evaluate the quality of antimalarial and antiretroviral medicines in Sahel countries, assessing site conditions, compliance of medicines with pharmacopoeia tests, formulation equivalence with a reference medicine, and the influence of climate on quality attributes. Ultra Performance Liquid Chromatography methods for eight active pharmaceutical ingredients were validated following the International Conference for Harmonization guideline for its detection and quantification. Quality control consists of visual inspections to detect any misinformation or imperfections and pharmacopeial testing to determine the quality of pharmaceutical products. Medicines which complied with uniformity dosage units and dissolution tests were stored under accelerated conditions for 6 months. Artemether\/Lumefantrine and Lopinavir\/Ritonavir formulations failed uniformity dosage units and disintegration tests respectively, detecting a total of 28.6% substandard medicines. After 6 months stored under accelerated conditions (40 \u00b0C \/\/ 75% relative humidity) simulating climatic conditions in Sahel countries, some medicines failed pharmacopeia tests. It demonstrated the influence of these two factors in their quality attributes. This study emphasizes the need of certified quality control laboratories as well as the need for regulatory systems to maintain standards in pharmaceutical manufacturing and distribution in these countries, especially when medicines are transported to rural areas where these climatic conditions are harsher.<\/jats:p>","DOI":"10.1371\/journal.pone.0303289","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:26:09Z","timestamp":1715275569000},"page":"e0303289","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality assessment of oral antimalarial and antiretroviral medicines used by public health systems in Sahel countries"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-9790","authenticated-orcid":true,"given":"Amor R.","family":"C\u00e1ceres-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9900-3169","authenticated-orcid":true,"given":"Javier","family":"Su\u00e1rez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-7824","authenticated-orcid":true,"given":"Ana","family":"Santove\u00f1a-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 B.","family":"Fari\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"pone.0303289.ref001","unstructured":"World Health Organization [Internet]. The top 10 causes of death. Dec 9, 2020 [Accessed 15 Sep, 2023]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"pone.0303289.ref002","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2012.02.021","article-title":"Outwitting evolution: Fighting drug resistance in the treatment of TB, malaria and HIV","volume":"148","author":"DE Goldberg","year":"2012","journal-title":"Cell"},{"volume-title":"WHO global surveillance and monitoring system for substandard and falsified medical products","year":"2017","author":"World Health Organization","key":"pone.0303289.ref003"},{"volume-title":"The path that ends AIDS: UNAIDS Global AIDS Update 2023","year":"2023","author":"Joint United Nations Programme on, HIV\/AIDS","key":"pone.0303289.ref004"},{"volume-title":"World Malaria Report 2022","year":"2022","author":"World Health Organization","key":"pone.0303289.ref005"},{"key":"pone.0303289.ref006","unstructured":"World Health Organization. WHO guidelines for malaria. Mar 14, 2023. https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria."},{"key":"pone.0303289.ref007","unstructured":"Lumefantrine [Accessed Sep 18, 2023]. Database: PubChem [Internet]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6437380."},{"key":"pone.0303289.ref008","unstructured":"Artemether [Accessed Sep 18, 2023]. Database: PubChem [Internet]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/68911."},{"key":"pone.0303289.ref009","unstructured":"UNAIDS [Internet]. HIV treatment. [Accessed Sep 18, 2023]. https:\/\/www.unaids.org\/en\/topic\/treatment."},{"key":"pone.0303289.ref010","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/pathogens10111377","article-title":"Human immunodeficiency virus type 2: The neglected threat","volume":"10","author":"G Ceccarelli","year":"2021","journal-title":"Pathogens"},{"key":"pone.0303289.ref011","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/ijms24065905","article-title":"Antiretroviral treatment of HIV-2 infection: Available drugs, resistance pathways, and promising new compounds","volume":"24","author":"I Moranguinho","year":"2023","journal-title":"Int J Mol Sci"},{"volume-title":"A study on the public health and socioeconomic impact of substandard and falsified medical products","year":"2020","author":"World Health Organization","key":"pone.0303289.ref012"},{"key":"pone.0303289.ref013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12981-017-0147-x","article-title":"Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in cameroon","volume":"14","author":"MPN Djobet","year":"2017","journal-title":"AIDS Res Ther"},{"key":"pone.0303289.ref014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40360-021-00514-w","article-title":"Quality of selected anti-retroviral medicines: Tanzania mainland market as a case study","volume":"22","author":"S Mziray","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0303289.ref015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2710.2007.00847.x","article-title":"Antimalarial drug quality in africa","volume":"32","author":"AA Amin","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"pone.0303289.ref016","doi-asserted-by":"crossref","first-page":"e96810","DOI":"10.1371\/journal.pone.0096810","article-title":"Quality of antimalarial drugs and antibiotics in papua new guinea: A survey of the health facility supply chain","volume":"9","author":"MW Hetzel","year":"2014","journal-title":"PLoS One"},{"key":"pone.0303289.ref017","first-page":"44","article-title":"The fundamentals of dissolution testing","volume":"43","author":"F Thomas","year":"2019","journal-title":"Pharm Tech"},{"key":"pone.0303289.ref018","unstructured":"Antimalarials [Accessed Sep 19, 2023]. Database: IDDO\/WWARN\u2014Medicine Quality Literature Surveyor [Internet]. https:\/\/www.iddo.org\/mqsurveyor\/#antimalarials."},{"key":"pone.0303289.ref019","unstructured":"Antiretrovirals [Accessed Sep 19, 2023]. Database: IDDO\/WWARN\u2014Medicine Quality Literature Surveyor [Internet]. https:\/\/www.iddo.org\/mqsurveyor\/#antiretrovirals."},{"key":"pone.0303289.ref020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1179\/1364859411Y.0000000030","article-title":"Quality of chloroquine tablets available in africa","volume":"105","author":"CW Sawadogo","year":"2011","journal-title":"Ann Trop Med Parasitol"},{"key":"pone.0303289.ref021","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/bcp.12298","article-title":"Substandard drugs: A potential crisis for public health","volume":"78","author":"A Johnston","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0303289.ref022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12936-017-1852-6","article-title":"Anti-malarial medicine quality field studies and surveys: A systematic review of screening technologies used and reporting of findings","volume":"16","author":"M Lalani","year":"2017","journal-title":"Malar J"},{"key":"pone.0303289.ref023","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12936-023-04600-8","article-title":"Pharmacopeial quality of artemether\u2013lumefantrine anti-malarial agents in uganda","volume":"22","author":"M Ocan","year":"2023","journal-title":"Malar J"},{"key":"pone.0303289.ref024","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1086\/383575","article-title":"Antiretroviral drug content in products from developing countries","volume":"38","author":"SR Penzak","year":"2004","journal-title":"Clin Infect Dis"},{"key":"pone.0303289.ref025","unstructured":"United Nations Office on Drugs and Crime. Trafficking in medical products in the sahel. 2022. https:\/\/www.unodc.org\/documents\/data-and-analysis\/tocta_sahel\/TOCTA_Sahel_medical_2023.pdf."},{"key":"pone.0303289.ref026","doi-asserted-by":"crossref","first-page":"e04900","DOI":"10.1016\/j.heliyon.2020.e04900","article-title":"Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?","volume":"6","author":"X Zhan","year":"2020","journal-title":"Heliyon"},{"key":"pone.0303289.ref027","doi-asserted-by":"crossref","first-page":"115386","DOI":"10.1016\/j.socscimed.2022.115386","article-title":"Antibiotic geographies and access to medicines: Tracing the role of india\u2019s pharmaceutical industry in global trade","volume":"312","author":"L Bjerke","year":"2022","journal-title":"Soc Sci Med"},{"key":"pone.0303289.ref028","unstructured":"International Conference Harmonisation. ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products. 2003. https:\/\/www.ema.europa.eu\/en\/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline."},{"key":"pone.0303289.ref029","article-title":"Responding to the surge of substandard and falsified health products triggered by the covid-19 pandemic","author":"NB Nagesh","year":"2021","journal-title":"USP"},{"key":"pone.0303289.ref030","unstructured":"Directive 2011\/62\/Eu Of The European Parliament And Of The Council of 8 June 2011 amending Directive 2001\/83\/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products."},{"key":"pone.0303289.ref031","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex 5: Guidelines on import procedures for medical products. World Health Organization. Oct 10, 2019. https:\/\/www.who.int\/publications\/m\/item\/annex-5-trs-1019."},{"key":"pone.0303289.ref032","unstructured":"ISACAM [Internet]. [Accessed Jan 10, 2022]. https:\/\/isacam.eu\/."},{"volume-title":"Chloroquine Phosphate Tablets","year":"2020","author":"United States Pharmacopeia","key":"pone.0303289.ref033"},{"volume-title":"Artemether and Lumefantrine Tablets","year":"2021","author":"Pharmacopeial Forum of United States Pharmacopeia","key":"pone.0303289.ref034"},{"volume-title":"Abacavir, Lamivudine and Zidovudine Tablets","year":"2021","author":"United Stated Pharmacopeia","key":"pone.0303289.ref035"},{"key":"pone.0303289.ref036","unstructured":"United States Pharmacopeia. Lopinavir and Ritonavir Tablets. May 01, 2021. Ed: USP-NF-Online. Baltimore."},{"key":"pone.0303289.ref037","unstructured":"International Conference Harmonisation. ICH Harmonised tripartite guideline Validation of Analytical Procedures: Text and Methodology Q2(R1). 2015. https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf."},{"key":"pone.0303289.ref038","first-page":"20150366","article-title":"Quantitative mass spectrometry methods for pharmaceutical analysis","volume":"374","author":"G Loos","year":"2016","journal-title":"Philos Trans A Math Phys Eng Sci"},{"key":"pone.0303289.ref039","unstructured":"European Pharmacopeia. 01\/2018:0478 Tablets. Council of Europe. Ed: 10.6. Strasbourg."},{"volume-title":"\u23292\u232a Oral Drug Products\u2014Product Quality Tests","year":"2019","author":"United States Pharmacopeia","key":"pone.0303289.ref040"},{"key":"pone.0303289.ref041","unstructured":"European Pharmacopeia. 01\/2008:20905 Uniformity of mass of single-dose preparations. Council of Europe. Ed: 10.6. Strasbourg."},{"key":"pone.0303289.ref042","unstructured":"European Pharmacopeia. 04\/2017:20940 Uniformity of dosage units. Council of Europe. Ed: 10.6. Strasbourg."},{"volume-title":"\u2329711\u232a DISSOLUTION","year":"2019","author":"United States Pharmacopeia","key":"pone.0303289.ref043"},{"key":"pone.0303289.ref044","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12936-020-03209-5","article-title":"Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether\/lumefantrine tablets","volume":"19","author":"S Belew","year":"2020","journal-title":"Malar J."},{"volume-title":"Abacavir and Lamivudine Tablets","year":"2021","author":"United States Pharmacopeia","key":"pone.0303289.ref045"},{"key":"pone.0303289.ref046","unstructured":"European Medicine Agency. Guideline on the investigation on the bioequivalence. 2010; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"pone.0303289.ref047","unstructured":"European Pharmacopeia. 01\/2022:20901 Disintegration of tablets and capsules. Council of Europe. Ed: 10.6. Strasbourg."},{"key":"pone.0303289.ref048","unstructured":"European Pharmacopeia. 01\/2010:20907 Friability of uncoated tablets. Council of Europe. Ed: 10.6. Strasbourg."},{"key":"pone.0303289.ref049","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12936-015-0563-0","article-title":"Efficacy of chloroquine for the treatment of plasmodium vivax in the saharan zone in mauritania","volume":"14","author":"AS Ould","year":"2015","journal-title":"Malar J"},{"key":"pone.0303289.ref050","doi-asserted-by":"crossref","first-page":"e011423","DOI":"10.1136\/bmjgh-2022-011423","article-title":"The quality of antiretroviral medicines: An uncertain problem","volume":"8","author":"Ngan T Do","year":"2023","journal-title":"BMJ Global Health"},{"journal-title":"Post-market assessment of the quality of first line regimen fixed-dose combination antiretrovirals in South Africa","year":"2017","author":"S Reem","key":"pone.0303289.ref051"},{"key":"pone.0303289.ref052","article-title":"Pharmacopeial quality of artemether\u2013lumefantrine anti-malarial agents in uganda","author":"Moses O","year":"2023","journal-title":"Malar J"},{"key":"pone.0303289.ref053","first-page":"65","article-title":"Electrospray ionization tandem mass spectrometry of the two main antimalarial drugs: Artemether and lumefantrine","volume":"23","author":"VGd Santos","year":"2012","journal-title":"J. Braz. Chem. Soc"},{"key":"pone.0303289.ref054","article-title":"Guide to achieving realiable quantitative LC-MS measurements","author":"M. Sargent","year":"2013","journal-title":"RSC Analytical Methods Committee"},{"key":"pone.0303289.ref055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpba.2019.03.021","article-title":"Chemometric study of the excipients\u2019 influence on polymorphic-behavior. mefenamic acid as case of study","volume":"170","author":"M Antonio","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"pone.0303289.ref056","article-title":"Blend segregation in tablets manufacturing and its effect on drug content Uniformity\u2014A review","author":"E Jakubowska","year":"2021","journal-title":"Pharmaceutics"},{"key":"pone.0303289.ref057","first-page":"34","article-title":"Justification of using weight variation instead of content uniformity for release of relevant OSD forms","volume":"47","author":"P Cholayudth","year":"2023","journal-title":"PharmTech"},{"key":"pone.0303289.ref058","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1365-3156.2002.00937.x","article-title":"In vitro evaluation of the quality of essential drugs on the tanzanian market","volume":"7","author":"PG Risha","year":"2002","journal-title":"Tropical Medicine and International Health"},{"key":"pone.0303289.ref059","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3390\/pharmaceutics14102096","article-title":"The effect of humidity on the dissolution kinetics and tablet properties of immediate-release tablet formulation containing lamotrigine","volume":"14","author":"M Lali\u0107-Popovi\u0107","year":"2022","journal-title":"Pharmaceutics"},{"key":"pone.0303289.ref060","unstructured":"European Pharmacopoeia. Chloroquine phosphate. Council of Europe. Ed: 11. Strasbourg."},{"key":"pone.0303289.ref061","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0099-5428(08)60315-9","article-title":"Chloroquine phosphate","volume":"5","author":"DD Hong","year":"1976","journal-title":"Analytical Profiles of Drug Substances"},{"issue":"130","key":"pone.0303289.ref062","article-title":"Guidance for Industry on ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing, and Controls Information; Availability","volume":"72","author":"Food and Drug Administration","year":"2007","journal-title":"The Federal Register \/ FIND"},{"key":"pone.0303289.ref063","doi-asserted-by":"crossref","first-page":"e0157039","DOI":"10.1371\/journal.pone.0157039","article-title":"Pharmaceutical equivalence of distributed generic antiretroviral (ARV) in asian settings: The cross-sectional surveillance study\u2013PEDA study","volume":"11","author":"V Sapsirisavat","year":"2016","journal-title":"PLoS One"},{"key":"pone.0303289.ref064","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.xphs.2021.08.037","article-title":"Comparative bioavailability of two formulations of biopharmaceutical classification system (BCS) class IV drugs: A case study of lopinavir\/ritonavir","volume":"110","author":"AM. Saeed","year":"2021","journal-title":"J Pharm Sci"},{"key":"pone.0303289.ref065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13318-022-00765-w","article-title":"A mechanistic absorption and disposition model of ritonavir to predict exposure and Drug\u2013Drug interaction potential of CYP3A4\/5 and CYP2D6 substrates","volume":"47","author":"S Arora","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"pone.0303289.ref066","unstructured":"Ritonavir [Accessed Sep 19, 2023]. Database: PubChem [Internet]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/392622."},{"key":"pone.0303289.ref067","unstructured":"Lopinavir [Accessed Sep 19, 2023]. Database: PubChem [Internet]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/92727."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:26:37Z","timestamp":1715275597000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303289"}},"subtitle":[],"editor":[{"given":"Sarah","family":"Nanzigu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0303289","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}